Compare CMTL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | CTSO |
|---|---|---|
| Founded | 1967 | 1997 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 45.7M |
| IPO Year | 2024 | 2008 |
| Metric | CMTL | CTSO |
|---|---|---|
| Price | $4.67 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $5.38 |
| AVG Volume (30 Days) | ★ 221.6K | 67.7K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | $1.97 | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $1.19 | $0.60 |
| 52 Week High | $6.21 | $1.39 |
| Indicator | CMTL | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 46.87 |
| Support Level | $2.74 | $0.62 |
| Resistance Level | $6.15 | $0.74 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 3.57 | 18.02 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.